Brain polyunsaturated lipids and neurodegenerative diseases

Nutraceuticals and Functional Foods: Natural Remedy

Volumn , Issue , 2014, Pages 387-412

  Díaz, Mario ^a   Marín, Raquel ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Alzheimer's disease; Human lipid diet; Lipid rafts; Nutraceuticals; Parkinson's disease; Polyunsaturated fatty acids

Indexed keywords

EID: 84927661931     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (130)

1. Akbar, M; Calderon, F; Wen, Z; Kim HY. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival.Proc Natl Acad Sci U S A., 2005, 102(31), 10858-63.
2. Akbar, M; Kim, HY.Protective effects of docosahexaenoic acid in staurosporine-induced apoptosis: involvement of phosphatidylinositol-3 kinase pathway. J Neurochem, 2002, 82(3), 655-65.
3. Alessandri, JM; Guesnet, P; Vancassel, S; Astorg, P; Denis, I; Langelier, B; Aïd, S; Poumès- Ballihaut, C; Champeil-Potokar, G; Lavialle, M.Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod Nutr Dev., 2004, 44(6), 509-38.
4. Almansa, E; Sánchez JJ; Cozzi, S; Rodríguez, C; Díaz, M. Temperature activity relationship for the intestinal Na+-K+-ATPase of Sparus aurata. A role for the phospholipid microenvironment?. J Comp Physiol B., 2003, 173, 231-237.
5. Barberger-Gateau, P; Letenneur, L; Deschamps, V; Pérès, K; Dartigues, JF; Renaud, S. Fish, meat, and risk of dementia: cohort study. BMJ, 2002, 325(7370), 932-3.
6. Barberger-Gateau, P; Raffaitin, C; Letenneur, L; et al.Dietary patterns and risk of dementia: The Three-City cohort study. Neurology, 2007, 69(20), 1921-1930.
7. Beal, MF.Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci., 2003, 991, 120-131.
8. Benarroch, EE.Lipid rafts, protein scaffolds, and neurologic disease. Neurology, 2007, 69(16), 1635-9.
9. Berg, L; McKeel, DW Jr, Miller, JP; Storandt, M; Rubin, EH; Morris, JC; Baty, J; Coats, M; Norton, J; Goate, AM; Price, JL; Gearing, M; Mirra, SS; Saunders, AM. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol., 1998, 55(3), 326-35.
10. Bishop, NA; Lu, T; Yankner, BA. Neural mechanisms of ageing and cognitive decline. Nature, 2010, 464, 529-535.
11. Boudrault, C; Bazinet, RP; Ma, DW.Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease. J Nutr Biochem., 2009, 20(1), 1-10.
12. Bousquet, M; Calon, F; Cicchetti, F. Impact of ω-3 fatty acids in Parkinson's disease. Ageing Res Rev., 2011, 10(4), 453-63.
13. Brown, DA; London, E.Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J. Biol. Chem., 2000, 275, 17221-17224.
14. Brugger, B; Graham, C; Leibrecht, I; Mombelli, E; Jen, A; Wieland, F; Morris, R. The membrane domains occupied by glycosylphosphatidylinositol-anchored prion protein and Thy-1 differ in lipid composition. J Biol Chem., 2004, 279, 7530-7536.
15. Burr, GO; Burr, MM. On the nature and role of fatty acids essential in nutrition. J Biol Chem, 1930, 86, 587-622.
16. Butterfield, DA; Lauderback, CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid betapeptide- associated free radical oxidative stress. Free Radic Biol Med., 2002, 32,1050-1060.
17. Calderon, F; Kim, HY. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem., 2004, 90(4), 979-88.
18. Calon, F. Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers. Curr Alzheimer Res., 2011, 8(5), 470-8.
19. Cansev, M; Wurtman, RJ. Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils. Neuroscience, 2007, 148(2), 421-31.
20. Cao, D; Xue, R; Xu, J; Liu, Z. Effects of docosahexaenoic acid on the survival and neurite outgrowth of rat cortical neurons in primary cultures. J Nutr Biochem., 2005, 16(9), 538-46.
21. Cao, D; Kevala, K; Kim, J; Moon, HS; Jun, SB; Lovinger, D; Kim, HY. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J Neurochem., 2009, 111(2), 510-21.
22. Christen, Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr, 2000, 71, 621S-629S.
23. Chung, WL; Chen, JJ; Su, HM. Fish oil supplementation of control and (n-3) fatty acid- deficient male rats enhances reference and working memory performance and increases brain regional docosahexaenoic acid levels. J Nutr., 2008, 138(6), 1165-71.
24. Cole, GM; Lim, GP; Yang, F; Teter, B; Begum, A; Ma, Q; Harris-White, ME; Frautschy, SA. Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging., 2005, 26 Suppl 1, 133-6.
25. Cole, GM; Ma, QL; Frautschy, SA. Dietary fatty acids and the aging brain. Nutr Rev., 2010, 68(2), S102-11.
26. Contreras, MA; Greiner, RS; Chang, MC; Myers, CS; Salem, N Jr; Rapoport, SI. Nutritional deprivation of alpha-linolenic acid decreases but does not abolish turnover and availability of unacylated docosahexaenoic acid and docosahexaenoyl-CoA in rat brain. J. Neurochem., 2000, 75, 2392-2400.
27. Cunnane, SC; Francescutti, V; Brenna, JT; Crawford, MA. Breast-fed infants achieve a higher rate of brain and whole-body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate. Lipids, 2000, 35, 105-111.
28. Cunnane, SC; Plourde, M; Pifferi, F; Bégin, M; Féart, C; Barberger-Gateau, P. Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res., 2009, 48(5), 239-56.
29. Dalfó, E; Portero-Otín, M; Ayala, V; Martínez, A; Pamplona, R; Ferrer, I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol., 2005, 64(9), 816-30.
30. Diaz, ML; Fabelo, N; Marin, R. Genotype-induced changes in biophysical properties of frontal cortex lipid raft from APP/PS1 transgenic mice. Front. Physiol., 2012, 3(3), 1-10.
31. Dillin, A; Cohen, E. Ageing and protein aggregation-mediated disorders: from invertebrates to mammals. Philos Trans R Soc Lond B Biol Sci., 2011, 366(1561), 94-8.
32. Duyckaerts, C; Dickson, DW. Neuropathology of Alzheimer's disease, D.W. Dickson (Ed.), Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, ISN Neuropath Press, Basel (2003), 47-65.
33. Duyckaerts, C; Potier, M-C; Delatour, B.A. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol, 2008, 115, 5-38.
34. Engelhart, MJ; Geerlings, MI; Ruitenberg, A; Van Swieten, JC; Hofman, A; Witteman, JC; Breteler, MM. Diet and risk of dementia: Does fat matter? The Rotterdam Study. Neurology, 2002, 59(12), 1915-21.
35. Esterbauer, H; Schaur, RJ; Zollner, H. Chemistry and biochemistry of 4αhydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med., 199, 11, 81-128.
36. Fabelo, N; Martín, V; Santpere, G; Marín, R; Torrent, L; Ferrer, I; Díaz, M. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med., 2011, 17(9-10), 1107-18.
37. Fabelo, N; Martín, V; Marín, R; Santpere, G; Aso, E; Ferrer, I; Díaz, M. Evidence for premature lipid raft aging in APP/PS1 double-transgenic mice, a model of familial Alzheimer disease. J Neuropathol Exp Neurol., 2012, 71(10), 868-81.
38. Farooqui, AA; Hirashima, Y; Horrocks, LA. Brain phospholipases and their role in signal transduction. Adv Exp Med Biol.,1992, 318, 11-25.
39. Farooqui, AA; Horrocks, LA; Farooqui, TJ. Deacylation and reacylation of neural membrane glycerophospholipids. Mol Neurosci., 2000a, 14(3), 123-35.
40. Farooqui, AA; Horrocks, LA; Farooqui, T.Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem Phys Lipids., 2000b, 106(1), 1-29.
41. Farooqui, AA. n-3 fatty acid-derived lipid mediators in the brain: new weapons against oxidative stress and inflammation. Curr Med Chem., 2012, 19(4), 532-43.
42. Féart, C; Samieri, C; Barberger-Gateau, P. Mediterranean diet and cognitive function in older adults. Curr Opin Clin Nutr Metab Care., 2010, 13(1), 14-8.
43. Feller, SE; Gawrisch, K. Properties of docosahexaenoic-acid-containing lipids and their influence on the function of rhodopsin. Curr Opin Struct Biol., 2005, 15(4), 416-22.
44. Fraser, T; Tayler, H; Love, S. Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem Res., 2010, 35(3), 503-13.
45. Gao, X; Cheng, H; Fung, TT; Logroscino, G; Schwarzschild, MA; Hu, FB; Ascherio, A. Prospective study of dietary pattern and risk of Parkinson disease. Ann. J. Clin. Nutr., 2007, 86, 1486-1494.
46. Goedert, M.Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci., 2001, 2(7), 492-501.
47. Gross, RW; Jenkins, CM; Yang, J; Mancuso, DJ; Han, X. Functional lipidomics: the roles of specialized lipids and lipid-protein interactions in modulating neuronal function Prostaglandins Other Lipid. Mediat., 2005, 77(1-4), 52-64.
48. Guan, Z; Wang, Y; Cairns, NJ; Lantos, PL; Dallner, G; Sindelar, PJ. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol., 1999, 58(7), 740-7.
49. Han, X. Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res., 2005, 2(1), 65-77.
50. He, C; Qu, X; Cui, L;Wang, J;Kang, JX. Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid. Proc Natl Acad Sci U S A., 2009, 106(27), 11370-5.
51. Irani, K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res., 2000, 87(3), 179-83.
52. Iwatsubo, T. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease. J Neurol., 2003, 250 Suppl 3, III11-4.
53. Jicha, GA; Markesbery, WR. Omega-3 fatty acids: potential role in the management of early Alzheimer's disease. Clin Interv Aging., 2010, 5, 45-61.
54. Joseph, MS; Ying, Z; Zhuang, Y; Zhong, H; Wu, A; Bhatia, HS;Cruz, R; Tillakaratne, NJ; Roy, RR; Edgerton, VR; Gomez-Pinilla, F. Effects of diet and/or exercise in enhancing spinal cord sensorimotor learning. PLoS One., 2012, 7(7), e41288.
55. Julien, C; Berthiaume, L; Hadj-Tahar, A; Rajput, AH; Bédard, PJ; Di Paolo, T; Julien, P; Calon, F. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem Int., 2006, 48(5), 404-14.
56. Jump, DB. The biochemistry of n- 3 polyunsaturated fatty acids. J. Biol. Chem., 2002, 277, 8755-8758.
57. Kaduce, TL; Chen, Y; Hell, JW; Spector, AA. Docosahexanoic acid synthesis from n-3 fatty acid precursors in rat hippocampal neurons. J Neurochem., 2008, 105(4), 1525-35.
58. Kalmijn, S. Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. J Nutr Health Aging., 2000, 4(4), 202-7.
59. Kalpouzos, G; Chételat, G; Baron, JC; Landeau, B; Mevel, K; Godeau, C; Barré, L; Constans, JM; Viader, F; Eustache, F; Desgranges, B. Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging., 2009, 30(1), 112-24.
60. Katakura, M; Hashimoto, M; Shahdat, HM; Gamoh, S; Okui, T; Matsuzaki, K; Shido, O. Docosahexaenoic acid promotes neuronal differentiation by regulating basic helix-loop- helix transcription factors and cell cycle in neural stem cells. Neuroscience, 2009, 160(3), 651-60.
61. Kawakita, E; Hashimoto, M; Shido, O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience, 2006, 139(3), 991-7.
62. Kim, HY; Akbar, M; Kim, YS. Phosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids, 2010, 82(4-6), 165-72.
63. Kobayashi, M; Nagata, S; Kita, Y; Nakatsu, N; Ihara, S; Kaibuchi, K; Kuroda, S; Ui, M; Iba, H; Konishi, H; Kikkawa, U; Saitoh, I; Fukui, Y. Expression of a constitutively active phosphatidylinositol 3-kinase induces process formation in rat PC12 cells. Use of Cre/loxP recombination system. J Biol Chem., 1997, 272(26), 16089-92.
64. Krentz, A; Viljoen, A; Sinclair, A. Insulin resistance: a risk marker for disease and disability in the older person. Diabet Med., 2012 doi: 10.1111/dme.12063.
65. Kroger, E; Verreault, R; Carmichael, PH; Lindsay, J; Julien, P; Dewailly, E; Ayotte, P; Laurin, D.Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am J Clin Nutr., 2009, 90(1), 184-92.
66. Laurin, D; Verreault, R; Lindsay, J; Dewailly, E; Holub, BJ. Omega-3 fatty acids and risk of cognitive impairment and dementia. J Alzheimers Dis., 2003, 5(4), 315-22.
67. Lebbadi, M; Julien, C; Phivilay, A; Tremblay, C; Emond, V; Kang, JX; Calon, F. Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease. J Alzheimers Dis., 2011, 27(4), 853-69.
68. Lee, AG. Lipid-protein interactions in biological membranes: a structural perspective. Biochim Biophys Acta., 2003, 1612(1), 1-40.
69. Lim, GP; Calon, F; Morihara, T; Yang, F; Teter, B; Ubeda, O; Salem, N Jr; Frautschy, SA; Cole, GM. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci., 2005, 25(12), 3032-40.
70. Litman, BJ; Mitchel, DC. A role for phospholipid polyunsaturation in modulating membrane protein function. Lipids, 1996, 31S, S193-S197.
71. Litman, BJ; Niu, SL; Polozova, A; Mitchell, DC. The role of docosahexaenoic acid containing phospholipids in modulating G protein-coupled signaling pathways: visual transduction. J Mol Neurosci., 2001, 16, 237-242.
72. Lowe, J; Mirra, SS; Hyman, B; Dickson, DW. Ageing and Dementia, S. Love, D.N. Louis, D.W. Ellison (Eds.), Greenfield's Neuropathology, vol. 1 Hodder Arnold, London. 2008: 1031-1152.
73. Lukiw, WJ; Bazan, NG. Docosahexaenoic acid and the aging brain. J Nutr., 2008, 138(12), 2510-2514.
74. Ma, D; Lu, L; Boneva, NB; Warashina, S; Kaplamadzhiev, DB; Mori, Y; Nakaya, MA; Kikuchi, M; Tonchev, AB; Okano, H; Yamashima, T. xpression of free fatty acid receptor GPR40 in the neurogenic niche of adult monkey hippocampus. Hippocampus, 2008, 18(3), 326-33.
75. Marin, R. Signalosomes in the brain: relevance in the development of certain neuropathologies such as Alzheimer's disease. Front Physiol., 2011, 2, 23.
76. Markesbery, WR; Kryscio, RJ; Lovell, MA; Morrow, JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol., 2005, 58(5), 730-735.
77. Martin, V; Fabelo, N; Santpere, G; Puig, B; Marín, R; Ferrer, I; Díaz, M. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimer's Dis., 2010, 19(2), 489-502.
78. Mattson, MP. Calcium and neurodegeneration. Aging cell, 2007, 6, 337-350.
79. Mitchell, DC; Niu, SL; Litman, BJ. Optimization of receptor-G protein coupling by bilayers lipid composition I. Kinetics of rhodopsintransducin binding. J Biol Chem., 2001, 276, 42801-42806.
80. Montine, TJ; Montine, KS; McMahan, W; Markesbery, WR; Quinn, JF; Morrow, JD. F2- isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal, 2005, 7(1-2), 269-275.
81. Moriguchi, T; Greiner, RS; Salem, N Jr. Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration. J Neurochem., 2000, 75(6), 2563-73.
82. Moriguchi, T; Salem, N Jr. Recovery of brain docosahexaenoate leads to recovery of spatial task performance. J Neurochem., 2003, 87(2), 297-309.
83. Morris, MC; Evans, DA; Bienias, JL; Tangney, CC; Bennett, DA; Wilson, RS; Aggarwal, N; Schneider, J. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol., 2003, 60(7), 940-6.
84. Morris, MC; Evans, DA; Tangney, CC; Bienias, JL; Wilson, RS. Fish consumption and cognitive decline with age in a large community study. Arch Neurol., 2005, 62(12) 1849-53.
85. Morris, MC. Nutritional determinants of cognitive aging and dementia. Proc Nutr Soc., 2012 71(1), 1-13.
86. Napier, JA; Michaelson, LV. Genomic and functional characterization of polyunsaturated fatty acid biosynthesis in Caenorhabditis elegans. Lipids, 2001, 36, 761-766.
87. Niemoller, TD; Stark, DT; Bazan, NG. Omega-3 fatty acid docosahexaenoic acid is the precursor of neuroprotectin D1 in the nervous system. In: Simopoulos AP, Bazan NG (eds) Omega-3 fatty acids, the brain and retina. World Rev Nutr Diet, 2009, 99, 46-54.
88. O'Brien, JS; Sampson, EL. Lipid composition of the normal human brain: gray matter, white matter, and myelin. J Lipid Res., 1965, 6(4), 537-544.
89. Olanow, CW. Oxidation reactions in Parkinson's disease. Neurology, 1990, 40(3), S-7.
90. Ono, K; Yamada, M. Vitamin A and Alzheimer's disease. Geriatr Gerontol Int., 2012, 12(2) 180-8.
91. Palacios-Pelaez, R; Lukiw, WJ; Bazan, NG. Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative disease. Mol Neurobiol., 2010, 41(2-3), 367-74.
92. Pawlosky, RJ; Hibbeln, JR; Novotny, JA; Salem, Jr N. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J Lipid Res., 2001, 42, 1257-65.
93. Pettegrew, JW; Klunk, WE; Panchalingam, K; McClure, RJ; Stanley, JA. Magnetic resonance spectroscopic changes in Alzheimer's disease. Ann N Y Acad Sci., 1997, 826, 282-306.
94. Pike, LJ; Han, X; Chung, KN; Gross, R.Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry, 2002, 41 2075-2088.
95. Pike, LJ. Lipid rafts: bringing order to chaos. J Lipid Res., 2003, 44, 655-667.
96. Plourde, M; Cunnane, SC. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physio Nutr Metab., 2007, 32,619-634.
97. Plourde, M; Fortier, M; Vandal, M; Tremblay-Mercier, J; Freemantle, E; Bégin, M; Pifferi, F Cunnane, SC. Unresolved issues in the link between docosahexaenoic acid and Alzheimer's disease. Prostaglandins Leukot Essent Fatty Acids, 2007, 77(5-6) 301-8.
98. Poirazi, P; Mel, BW. Impact of active dendrites and structural plasticity on the memory capacity of neural tissue. Neuron., 2001, 29(3), 779-96.
99. Prasad, MR; Lovell, MA; Yatin, M; Dhillon, H; Markesbery, WR. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res., 1998, 23(1), 81-88.
100. Robinson, PJ; Noronha, J; DeGeorge, JJ; Freed, LM; Nariai, T; Rapoport, SI. A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: review and critical analysis. Brain Res Brain Res Rev., 1992, 17 187-214.
101. Robson, LG; Dyall, S; Sidloff, D; Michael-Titus, AT. Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurons throughout development and in aged animals. Neurobiol Aging, 2010, 31(4), 678-87.
102. Russo, GL.Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinica implications in cardiovascular prevention. Biochem Pharmacol., 2009, 77(6), 937-46.
103. Sakamoto, T; Cansev, M; Wurtman, RJ. Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res., 2007, 1182, 50-9.
104. Saw, CL; Huang, Y; Kong, AN.S ynergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem Pharmacol., 2010, 79(3), 421-30.
105. Schaefer, EJ; Bongard, V; Beiser, AS; Lamon-Fava, S; Robins, SJ; Au, R; Tucker, KL; Kyle, DJ; Wilson, PW; Wolf, PA. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol., 2006, 63(11), 1545-50.
106. Scheltens, P; Kamphuis, PJ; Verhey, FR; Olde Rikkert, MG; Wurtman, RJ; Wilkinson, D; Twisk, JW; Kurz, A. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement, 2010, 6(1), 1-10.
107. Schmitz, G; Ecker, J. The opposing effects of n - 3 and n - 6 fatty acids. Prog Lipid Res. 2008:47:147-155
108. Serhan, CN; Chiang, N; Van Dyke, TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol, 2008, 8(5),349-361
109. Serhan, CN; Petasis, NA. Resolvins and protectins in inflammation resolution. Chem Rev., 2011, 111(10), 5922-43.
110. Simons, K; Toomre, D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol., 2000, 1, 31-39.
111. Simopoulos, AP. Evolutionary aspects of diet: fatty acids, insulin resistance and obesity. in: Obesity: New Directions in Assessment and Management. T. B. Van Itallie and A. P. Simopoulos, ed. Charles Press, Philadelphia, PA. 1995, 241-261.
112. Simopoulos, AP. Evolutionary aspects of omega-3 fatty acids in the food supply. Prostaglandins Leukotr Essent Fatty Acids, 1999, 60, 421-429.
113. Simopoulos, AP. Human requirement for n-3 polyunsaturated fatty acids. Poult Sci., 2000, 79(7), 961-70.
114. Singh, M; Dang, TN; Arseneault, M; Ramassamy, C. Role of by-products of lipid oxidation in Alzheimer's disease brain: a focus on acrolein. J Alzheimers Dis., 2010, 21(3), 741-56.
115. Söderberg, M; Edlund, C; Kristensson, K; Dallner, G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids, 1991, 26(6), 421-5.
116. Söderberg, M; Edlund, C; Alafuzoff, I; Kristensson, K; Dallner, G. Lipid composition in different regions of the brain in Alzheimer's disease/seniledementiaof Alzheimer's type. J Neurochem., 1992, 59(5), 1646-53.
117. Steele, M; Stuchbury, G; Münch, G. The molecular basis of the prevention of Alzheimer's disease through healthy nutrition. Exp Gerontol., 2007, 42(1-2), 28-36.
118. Stillwell, W; Wassall, SR. Docosahexaenoic acid: Membrane properties of a unique fatty acid. Chem Phys Lipids, 2003, 126, 1-27.
119. Su, HM. Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. J Nutr Biochem., 2010, 21(5), 364-73.
120. Sutachan, JJ; Casas, Z; Albarracin, SL; Stab, BR 2nd; Samudio, I; Gonzalez, J; Morales, L; Barreto, GE. Cellular and molecular mechanisms of antioxidants in Parkinson's disease, 2012, 15(3), 120-6.
121. Thomann, PA; Wüstenberg, T; Nolte, HM; Menzel, PB; Wolf, RC; Essig, M; Schröder, J. Hippocampal and entorhinal cortex volume decline in cognitively intact elderly. Psychiatry Res., 2012 doi:S0925-4927(12)00126-6.
122. Tocher, DR. Fatty acid requirements in ontogeny of marine and freshwater fish Aquacult. Res., 2010, 41, 717-732.
123. Tsui-Pierchala, B; Encinas, M; Milbrandt, J; Johnson, EM. Lipid rafts in neuronal signalling and function. Trends Neuroscience, 2002, 25(8), 412-417.
124. Vassallo, N; Scerri, C. Mediterranean Diet and Dementia of the Alzheimer Type. Curr Aging Sci., 2012 (in press).
125. Whelan, J; Rust, C. Innovative dietary sources of n-3 fatty acids. Annu Rev Nutr., 2006, 26, 75-103.
126. Wu, H; Ichikawa, S; Tani, C; Zhu, B; Tada, M; Shimoishi, Y; Murata, Y; Nakamura, Y. Docosahexaenoic acid induces ERK1/2 activation and neuritogenesis via intracellular reactive oxygen species production in human neuroblastoma SH-SY5Y cells. Biochim Biophys Acta., 2009, 1791(1), 8-16.
127. Yang, F; Lim, GP; Begum, AN; Ubeda, OJ; Simmons, MR; Ambegaokar, SS; Chen, PP; Kayed, R; Glabe, CG; Frautschy, SA; Cole, GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem., 2005, 280(7), 5892-901.
128. Youdim, KA; Martin, A; Joseph, JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci., 2000, 18(4-5), 383-99.
129. Young, G; Conquer, J.Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev., 2005, 45(1), 1-28.
130. Zipp, F; Aktas, O.The brain as a target of inflammation: Common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci., 2006, 29, 518-527.